English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Monday, April 2, 2018
Eisai Submits Supplemental New Drug Application to U.S. FDA
エーザイ、抗てんかん剤「Fycompa(R)」について米国で小児てんかんに係る適応で承認申請を提出
Friday, March 30, 2018
エーザイ、B型ボツリヌス毒素製剤「Neurobloc(R)」の欧州における権利をSloan Pharma社に譲渡
Wednesday, March 28, 2018
Eisai and Nichi-Iko Pharmaceutical Enter Into Strategic Alliance Agreement
エーザイ株式会社と日医工株式会社の戦略提携に関するお知らせ
Friday, March 23, 2018
AbbVie and Eisai Obtain Additional Approval for New Indication of Fully Human Anti-TNF-alpha Monoclonal
Eisai: Anticancer Agent LENVIMA Approved for Additional Indication of Unresectable Hepatocellular Carcinoma (HCC) in Japan
Monday, November 7, 2022
Eisai to Divest Rights for Muscle Relaxant Myonal, Vertigo, and Equilibrium Disturbance Treatment Merislon in Asia to DKSH
エーザイ、筋緊張改善剤「ミオナール(R)」、めまい・平衡障害治療剤「メリスロン(R)」についてアジアにおける権利をDKSHに譲渡
Friday, November 4, 2022
エーザイ、タイにおいてThai Life Insuranceとアルツハイマー病をはじめとする認知症の治療に対するアクセス支援に向けた協働について合意

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575